ImCheck Therapeutics receives EMA Orphan Drug Designation for ICT01 for treatment for acute myeloid leukemia: Marseille, France Thursday, July 24, 2025, 15:00 Hrs [IST] ImCheck Th ...

French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Roche AG’s Genentech unit disclosed outcomes of two studies testing IL-33-targeting astegolimab vs. placebo on top of standard-of-care maintenance therapy in subjects with moderate to very severe ...

Investing.com -- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Ahead of an opt-in decision on a PCSK9 inhibitor candidate, Eli Lilly is reported to be in advanced takeover negotiations with Verve Therapeutics ...